Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3180-3180
Open Access | Times Cited: 16

Showing 16 citing articles:

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 64
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Zhipeng Cao, Sadia Quazi, Sakshi Arora, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 1
Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment
Yan Peng, Pengfei Zhang, Wuxuan Mei, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131524-131524
Closed Access | Times Cited: 5
Different Mutational Landscapes in Human Papillomavirus–Induced and Human Papillomavirus–Independent Invasive Penile Squamous Cell Cancers
Mikhail Ermakov, Karl Kashofer, Sigrid Regauer
Modern Pathology (2023) Vol. 36, Iss. 10, pp. 100250-100250
Open Access | Times Cited: 12
Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
Chi Hoa Pham, Daenielle Lang, Wade T. Iams
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 5, pp. 100511-100511
Open Access | Times Cited: 9
Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
Mojca Unk, Barbara Jezeršek Novaković, Srdjan Novaković
Cancers (2023) Vol. 15, Iss. 5, pp. 1498-1498
Open Access | Times Cited: 7
Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach
Katiuscia Pagano, Roberta Listro, Pasquale Linciano, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106529-106529
Open Access | Times Cited: 5
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon
Journal of Korean Medical Science (2024) Vol. 39, Iss. 43
Open Access | Times Cited: 1
FGF receptor kinase inhibitors exhibit broad antiviral activity by targeting Src family kinases
D Stefanova, Dominik Olszewski, Mirco Glitscher, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 1
The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma
Samantha M. Ruff, Sameek Roychowdhury, Timothy M. Pawlik
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 7, pp. 779-788
Closed Access | Times Cited: 3
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, et al.
Cancer Research and Treatment (2023)
Open Access | Times Cited: 3
Supplementary Table S9 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
(2024)
Open Access
Supplementary Table S9 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric‐Bernstam, Antoine Hollebecque, Junji Furuse, et al.
(2024)
Open Access
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib
Ludovica Gnagni, Ilary Ruscito, Ilaria Grazia Zizzari, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 202, pp. 104464-104464
Open Access
The future is here—targeted therapies are coming of age in biliary tract cancers
Daniel Neureiter, Matthias Ocker
Chinese Clinical Oncology (2023) Vol. 12, Iss. 3, pp. 20-20
Open Access | Times Cited: 1
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions
Daniel Neureiter, Peter Ellinghaus, Matthias Ocker
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 17, pp. 1833-1837
Open Access | Times Cited: 1
Page 1

Scroll to top